Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073563 · ClinicalTrials.gov registry record · NA
Transforaminal Lumbar Interbody Fusion (TLIF)
A NA study of Degenerative Disease of the Lumbosacral Spine, sponsored by Medtronic Spinal and Biologics.
- Active
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT04073563: Active NA study of Degenerative Disease of the Lumbosacral Spine, sponsored by Medtronic Spinal and Biologics.
NCT04073563 is a NA study of Degenerative Disease of the Lumbosacral Spine that is active but no longer recruiting, run by Medtronic Spinal and Biologics. The registered enrollment target is 600 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04073563, a NA study of Degenerative Disease of the Lumbosacral Spine, is active but no longer recruiting, sponsored by Medtronic Spinal and Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 600 subjects will be enrolled and treated. The purpose of the study is to provide safety and effectiveness data of Infuse™ in Transforaminal Lumbar Interbody Fusion (TLIF) procedures and to obtain indication expansion for Infuse™ use in one and two level TLIF procedures.
Primary Outcome
Overall success is defined as the participant who meet the following five criteria: * Pain/disability (ODI) success, defined as at least a 15-point improvement from baseline; * Fusion success as defined in primary outcome 2. * Neurological success, defined as maintenance or improvement in neurological status; * No SAE related to the TLIF grafting material or interbody device; and * No secondary surgeries at index level that are related to the TLIF grafting material or interbody device
Conditions Studied
Interventions
- DEVICE Infuse™ Bone Graft (Infuse™)
- DEVICE Intervertebral body fusion device and Medtronic posterior Fixation Systems
Study Locations (20)
Florida
- Advent Health Altamonte Springs - Altamonte Springs
- Mayo Clinic - Jacksonville
- Advent Health Orlando - Orlando
- Orlando Health - Orlando
- Foundation for Orthopaedic Research and Education - Tampa
California
- University of California Irvine - Irvine
- Memorial Health Services - Laguna Hills
- Cedars Sinai Spine Center - Los Angeles
- University of California Davis Medical Center - Sacramento
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- Boulder Neurosurgical Associates and Justin Parker Neurological Institute/E. Lee Nelson - Boulder
- Vail-Summit Orthopaedics and Neurosurgery - Vail
Indiana
- Goodman Campbell Brain and Spine - Carmel
- Indiana Spine Group - Carmel
- OrthoIndy Northwest Office - Indianapolis
Arizona
- Mayo Clinic - Phoenix
- University of Arizona - Tucson
Connecticut
- Hartford Hospital - Hartford
Illinois
- Rush University Medical Center - Chicago
Iowa
- University of Iowa Hospitals and Clinic - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2028-07 |
| Phase | NA |
What the registry record for NCT04073563 still lists
NCT04073563 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Degenerative Disease of the Lumbosacral Spine appearing as the primary indexed condition, and to 2 interventions - of which Infuse™ Bone Graft (Infuse™) is the first listed.
NCT04073563 names 20 study sites across 8 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04073563 about?
NCT04073563 is a clinical study titled "Transforaminal Lumbar Interbody Fusion (TLIF)". This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 600 subje...
What is the current status of trial NCT04073563?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2019-12-19. Estimated completion is 2028-07.
What conditions does trial NCT04073563 study?
This clinical trial studies the following conditions: Degenerative Disease of the Lumbosacral Spine.
What interventions are being tested in trial NCT04073563?
The interventions under investigation include: Infuse™ Bone Graft (Infuse™) (DEVICE), Intervertebral body fusion device and Medtronic posterior Fixation Systems (DEVICE).
Who is sponsoring clinical trial NCT04073563?
This trial is sponsored by Medtronic Spinal and Biologics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04073563 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04073563's enrollment target sits among peer trials
600 162nd of 2000 higher than 1,827 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI